Home
About Us
Products
Manus Aktteva Biopharma LLP, an ISO 9001: 2008 certified sourcing & export concern takes pride in fulfilling your requirements of Nutraceuticals, Specialty Chemicals, Pharmaceutical APIs and their advance level intermediates from ISO Certified, GMP, CGMP & USFDA approved units with supportive regulatory documentations like DMF, EDMF, COS, USDMF etc. We wish to state that anyone interested in sourcing any special molecules, APIs, Intermediates, Chiral Compounds etc. and feels it is difficult for early completion of tasks, please call on us and TEST US TO GET THE BEST OF US.
Category
Recommended
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1)
Enquiry
Quick Links
Blog
Contact Us

Tacrolimus monohydrate (CAS No.: 109581-93-3)

Manus Aktteva Biopharma LLP is an ISO 9001:2015 Certified Global Supplier based in India for the product Tacrolimus monohydrate, 109581-93-3.
We offer the product Tacrolimus monohydrate, 109581-93-3 from our manufacturer / supplier / principals for your Research and Development / Evaluation or Commercial requirements, based on the product's availability from our network. We can also offer Tacrolimus monohydrate, 109581-93-3 intermediates with the supportive technical package required for evaluation.
We respect our customer's requirements of strict regulatory compliance and specification needs by offering the API - Active Pharmaceutical Ingredients and intermediates transparently while offering easy access to manufacturer / supplier / principals with affordable and high-quality raw materials.
If you are looking for the API -Active Pharmaceutical Ingredients Tacrolimus monohydrate, 109581-93-3 manufacturer supplier who is reliable and meets your required quality standard requirements in the first place, you are at the right place!

CAS number:

109581-93-3

Chemical Name:

(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-Hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8, Tacrolimus monohydrate (CAS No.: 109581-93-3)

Manufacturer Certificate:

GMP, EUGMP, USFDA

Application:

For R&D Purpose

Properties
Related Intermediates

Synonym

(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-Hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propen-1-yl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)tetrone, Tacrolimus monohydrate (CAS No.: 109581-93-3)

Molecular Formula

C44H69NO12.H2O

Molecular Weight

822.03

Manufacturer Specifications

Available on request

Packing

Export worthy packing

Material Safety Data Sheet

Available on request

Availability

Sample available

Comments

It is also used in a topical preparation in the treatment of atopic dermatitis (eczema), severe refractory uveitis after bone marrow transplants, exacerbations of minimal change disease

The list of intermediates for Tacrolimus monohydrate (CAS No.: 109581-93-3) will be updated soon.

If you can not locate your required intermediate for Tacrolimus monohydrate (CAS No.: 109581-93-3) on this page, you may send us a sourcing request for the specific Tacrolimus monohydrate (CAS No.: 109581-93-3) intermediate you are looking for along with its Cas No., and the Intermediate name and we shall come back to you promptly with more details. Please click here to send an email.

Please note that Manus Aktteva Biopharma LLP website is a dynamic one with the new contents revised/updated regularly. Hence it would be most beneficial for you to visit the website again and again till you gain!

Our customers expect a prompt response on both the quotes and delivery of the product. As a general rule, we respond to new enquiry within 48 hours after the initial screening of product availability and supply ability if the material is not in stock. If any project is initiated already, we provide each customer with a report as to when we can offer you the requested product along with the actual status of the synthesis of the project. This facilitates real-time feedback to our customers.

We listen carefully to our customer's concerns and needs and address each of their requirements promptly and effectively.

Description:

is an immunosuppressive drug used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and to lower the risk of organ rejection.

Manufacturer Documentation / Approvals :

USDMF	EDMF	PMDA - JAPAN	DMF - CANADA	TGA - AUSTRALIA	DMF (OPEN PART)	DMF (CLOSED PART)	MEDSAFE - NEW ZEALAND	HEALTH CANADA	JDMF

Products protected by valid patents from a manufacturer are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
Products currently covered by valid US Patents are offered for R&D use from a manufacturer in accordance with 35 USC 271 +A13(1)
Products falling in to controlled substance category / list of schedule drugs shall be exported directly from the manufacturer principals only against receipt of original import permission issued by concerned authorities of the importing country.
Manus Aktteva Biopharma LLP assumes no responsibility/liability in case of being imparted with goods which infringe intellectual property in any manner whatsoever which includes patent rights of any individual manufacturer. Manus Aktteva makes no representations or warranties of any kind, express or implied, about the originality or reliability with respect to the intellectual property which includes patents of a manufacturer in its products or services for any purpose.
Manus Aktteva Biopharma LLP warns the sellers not to sell any goods which infringe intellectual property in any manner whatsoever which includes patent rights of any individual or a manufacturer.
Manus Aktteva Biopharma LLP warns the buyers not to use/procure any goods from a manufacturer to achieve a product which might be knowingly causing an infringement of intellectual property in any manner whatsoever which includes patent rights of any individual manufacturer.
This website is updated and maintained by Manus Aktteva Biopharma LLP. As a matter of policy, Manus Aktteva Biopharma LLP does not entertain any anonymous or pseudonymous inquiries.

Are you looking for Tacrolimus monohydrate (CAS No.: 109581-93-3) with documentation like CEP / COS, MHRA - UK, DMF - KOREA, AIFA - ITALY, TDP, JAPAN - AFM, DMF - CTD, DCGI, ICH, COPP, TDMF, Written Confirmation? Please click here to send us sourcing request.

Why Us